Telbivudine decreases proportion of peripheral blood CD4+CD25+CD127low T cells in parallel with inhibiting hepatitis B virus DNA

Yan,Zehui; Zhou,Jijun; Zhang,Mengjun; Fu,Xiaolan; Wu,Yuzhang; Wang,Yuming

doi:10.3892/mmr.2014.2042

Telbivudine decreases proportion of peripheral blood CD4+CD25+CD127low T cells in parallel with inhibiting hepatitis B virus DNA

Authors:
- Zehui Yan
- Jijun Zhou
- Mengjun Zhang
- Xiaolan Fu
- Yuzhang Wu
- Yuming Wang
View Affiliations

Affiliations: Institute of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing 400038, P.R. China, Institute of Immunology, Third Military Medical University, Chongqing 400038, P.R. China
Published online on: March 12, 2014 https://doi.org/10.3892/mmr.2014.2042
Pages: 2024-2030

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Regulatory T cells (Treg) have significant roles in the immunopathology of patients with chronic hepatitis B (CHB) and exhibit an evident correlation with antiviral immunity when antiviral therapy is applied. In order to investigate how circulating Tregs are affected by telbivudine treatment and its significance in patients with CHB, peripheral blood mononuclear cells (PBMCs) were isolated and the proportions of circulating cluster of differentiation (CD)4+CD25+CD127low and CD8+CD25+ T cells of CHB patients prior to and during the three or six months of treatment were assessed and detected by flow cytometric analysis. The levels of forkhead/winged helix transcription factor (Foxp3) mRNA were also quantified using quantitative polymerase chain reaction. A significantly higher percentage of CD4+CD25+CD127low and CD8+CD25+ T cells in the PBMCs of patients with CHB were identified compared with that of healthy individuals. Patients with CHB also demonstrated significantly higher levels of Foxp3 mRNA compared with that of healthy individuals. Following six months of telbivudine treatment, the proportion of circulating CD4+CD25+CD127low and CD8+CD25+ T cells and the relative levels of Foxp3 mRNA in patients with CHB was comparable to the proportion in healthy individuals. The proportions of circulating peripheral blood CD4+CD25+CD127low T cells were paralleled with its HBV DNA inhibition. The results of the present study indicate that telbivudine treatment reduces HBV DNA levels rapidly and indirectly affects the immune system by downregulating the proportion of circulating Treg markedly, which may be beneficial to restore the antiviral immune response.

View Figures

View References

1	Lai CL, Ratziu V, Yuen MF and Poynard T: Viral hepatitis B. Lancet. 362:2089–2094. 2003. View Article : Google Scholar : PubMed/NCBI
2	Guidotti LG and Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol. 1:23–61. 2006. View Article : Google Scholar : PubMed/NCBI
3	Rehermann B, Fowler P, Sidney J, et al: The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med. 181:1047–1058. 1995. View Article : Google Scholar : PubMed/NCBI
4	Bertoletti A and Naoumov NV: Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol. 39:115–124. 2003. View Article : Google Scholar : PubMed/NCBI
5	Bertoletti A, D’Elios MM, Boni C, et al: Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology. 112:193–199. 1997. View Article : Google Scholar : PubMed/NCBI
6	Zhang Z, Zhang JY, Wang LF and Wang FS: Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatol. 27:223–230. 2012. View Article : Google Scholar : PubMed/NCBI
7	Sakaguchi S, Yamaguchi T, Nomura T and Ono M: Regulatory T cells and immune tolerance. Cell. 133:775–787. 2008. View Article : Google Scholar : PubMed/NCBI
8	Miyara M and Sakaguchi S: Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 13:108–116. 2007. View Article : Google Scholar
9	Xu D, Fu J, Jin L, et al: Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol. 177:739–747. 2006.
10	Stoop JN, van der Molen RG, Baan CC, et al: Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 41:771–778. 2005. View Article : Google Scholar : PubMed/NCBI
11	Franzese O, Kennedy PT, Gehring AJ, et al: Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol. 79:3322–3328. 2005.
12	Feng IC, Koay LB, Sheu MJ, et al: HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection. J Biomed Sci. 14:43–57. 2007.
13	Taams LS, Vukmanovic-Stejic M, Smith J, et al: Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. Eur J Immunol. 32:1621–1630. 2002.
14	Liaw YF and Chu CM: Hepatitis B virus infection. Lancet. 373:582–592. 2009. View Article : Google Scholar : PubMed/NCBI
15	Dienstag JL: Hepatitis B virus infection. N Engl J Med. 359:1486–1500. 2008. View Article : Google Scholar : PubMed/NCBI
16	Sprengers D, Stoop JN, Binda RS, et al: Induction of regulatory T-cells and interleukin-10-producing cells in non-responders to pegylated interferon-alpha therapy for chronic hepatitis B. Antivir Ther. 12:1087–1096. 2007.PubMed/NCBI
17	Rico MA, Quiroga JA, Subirá D, et al: Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha. Hepatology. 33:295–300. 2001. View Article : Google Scholar : PubMed/NCBI
18	Maini MK, Reignat S, Boni C, et al: T cell receptor usage of virus-specific CD8 cells and recognition of viral mutations during acute and persistent hepatitis B virus infection. Eur J Immunol. 30:3067–3078. 2000. View Article : Google Scholar : PubMed/NCBI
19	Boni C, Penna A, Bertoletti A, et al: Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol. 39:595–605. 2003. View Article : Google Scholar : PubMed/NCBI
20	Tsai SL, Sheen IS, Chien RN, et al: Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci. 10:120–135. 2003. View Article : Google Scholar : PubMed/NCBI
21	Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG and Janssen HL: Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology. 361:141–148. 2007. View Article : Google Scholar : PubMed/NCBI
22	Chen Y, Li X, Ye B, et al: Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res. 91:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
23	Koay LB, Feng IC, Sheu MJ, et al: Hepatitis B virus (HBV) core antigen-specific regulatory T cells confer sustained remission to anti-HBV therapy in chronic hepatitis B with acute exacerbation. Hum Immunol. 72:687–698. 2011. View Article : Google Scholar : PubMed/NCBI
24	Nash K: Telbivudine in the treatment of chronic hepatitis B. Adv Ther. 26:155–169. 2009. View Article : Google Scholar : PubMed/NCBI
25	Lai CL, Gane E, Liaw YF, et al: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 357:2576–2588. 2007. View Article : Google Scholar : PubMed/NCBI
26	Lai CL, Leung N, Teo EK, et al: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 129:528–536. 2005.PubMed/NCBI
27	Lai CL, Gane E, Hsu CW, et al: Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine Hepatology. 44(Suppl 1): 222A2006.
28	Liaw YF, Gane E, Leung N, et al: 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 136:486–495. 2009. View Article : Google Scholar : PubMed/NCBI
29	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society for Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl). 120:2159–2173. 2007.PubMed/NCBI
30	Shaik GM, Dráberová L and Dráber P, Boubelík M and Dráber P: Tetraalkylammonium derivatives as real-time PCR enhancers and stabilizers of the qPCR mixtures containing SYBR Green I. Nucleic Acids Res. 36:e932008. View Article : Google Scholar : PubMed/NCBI
31	Lan RY, Cheng C, Lian ZX, et al: Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology. 43:729–737. 2006. View Article : Google Scholar : PubMed/NCBI
32	Li S, Gowans EJ, Chougnet C, Plebanski M and Dittmer U: Natural regulatory T cells and persistent viral infection. J Virol. 82:21–30. 2008. View Article : Google Scholar
33	Fontenot JD and Rudensky AY: A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 6:331–337. 2005. View Article : Google Scholar : PubMed/NCBI
34	Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 4:330–336. 2003.
35	Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
36	Yang G, Liu A, Xie Q, et al: Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int Immunol. 19:133–140. 2007.
37	Belkaid Y: Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol. 7:875–888. 2007. View Article : Google Scholar : PubMed/NCBI
38	Belkaid Y and Rouse BT: Natural regulatory T cells in infectious disease. Nat Immunol. 6:353–360. 2005. View Article : Google Scholar : PubMed/NCBI
39	Alatrakchi N and Koziel M: Regulatory T cells and viral liver disease. J Viral Hepat. 16:223–229. 2009. View Article : Google Scholar : PubMed/NCBI
40	Rushbrook SM, Hoare M and Alexander GJ: T-regulatory lymphocytes and chronic viral hepatitis. Expert Opin Biol Ther. 7:1689–1703. 2007. View Article : Google Scholar : PubMed/NCBI
41	Billerbeck E, Bottler T and Thimme R: Regulatory T cells in viral hepatitis. World J Gastroenterol. 13:4858–4864. 2007.PubMed/NCBI
42	Aandahl EM, Michaëlsson J, Moretto WJ, Hecht FM and Nixon DF: Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol. 78:2454–2459. 2004.
43	Cabrera R, Tu Z, Xu Y, et al: An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology. 40:1062–1071. 2004.
44	Lau GK, Cooksley H, Ribeiro RM, et al: Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther. 12:705–718. 2007.PubMed/NCBI
45	Peng G, Li S, Wu W, Sun Z, Chen Y and Chen Z: Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology. 123:57–65. 2008.
46	Cao D, Malmström V, Baecher-Allan C, Hafler D, Klareskog L and Trollmo C: Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol. 33:215–223. 2003.PubMed/NCBI